Dr. Daniel J. Drucker is University Professor in the Department of Medicine's Division of Endocrinology, University of Toronto; the Banting and Best Diabetes Centre-Novo Nordisk Chair in Incretin Biology; and a Senior Investigator at Sinai Health's Lunenfeld-Tanenbaum Research Institute.
The Drucker Lab's studies of the physiology and molecular biology of the glucagon-like peptides have continuously advanced the science of peptide hormones and our understanding of their therapeutic potential. Dr. Drucker's foundational work has underpinned the development of two classes of medicine for type 2 diabetes (GLP-1 receptor agonists and DPP-4 inhibitors). He has also led the identification of the cardioprotective mechanisms of GLP-1 action, predicting the safety of GLP-1 receptor agonists for treatment of obesity and other chronic conditions. Most recently, the Drucker Lab has identified multiple mechanisms linking GLP-1 to the reduction of inflammation.
Dr. Drucker's scientific discoveries have resulted in 33 US patents supporting translational drug development efforts in the field of peptide-based therapeutics. He has been recognized as a Fellow of the Royal Society and the Royal Society of Canada; International Member of the US National Academies of Science and Medicine; and an inductee of the Canadian Medical Hall of Fame.
Curriculum VitaeGoogle Scholar Profile
DiscoverResearch Profile
Selected Recent Awards
Frontiers of Knowledge Award for Biology and Biomedicine, Fundacion BBVA, Spain, 2025
Breakthrough Prize in Life Sciences USA 2025
Warren Triennial Prize, Massachusetts General Hospital, Harvard University 2025
Time100 Most Influential People, Time Magazine, 2024
Princess of Asturias Award for Technical and Scientific Research, Princess of Asturias Foundation, Spain, 2024
VinFuture Prize for Innovators with Outstanding Achievements in Emerging Fields, VinFuture Foundation, Vietnam, 2023
Wolf Prize in Medicine, Wolf Foundation, Israel, 2023
Canada Gairdner International Award, Gairdner Foundation, 2021
Warren Alpert Foundation Prize, Warren Alpert Foundation, United States, 2020
Disclosure: Dr. Drucker maintains this Website and is responsible for Website content. Dr. Drucker has served as a speaker within the past 12 months for Novo Nordisk Inc, and Boehringer Ingelheim, and as a consultant to Amgen, AstraZeneca, Kallyope and Pfizer Inc. Neither Dr. Drucker or his family members hold issued stock directly or indirectly in any of these companies. DJD holds non-exercised options in Kallyope. GLP-2 is the subject of a patent license agreement between Takeda Inc and the University of Toronto, Toronto General Hospital (UHN) and Daniel Drucker.